Finally, when we used the sigE mutant as subcutaneous vaccine, it was able to induce a higher level of protection than did BCG with both H37Rv and a highly virulent strain of M. tuberculosis (Beijing code 9501000).
INTRODUCTION
Cycling conditions used were: initial denaturation at 95ºC for 15 min, followed by 40 cycles at 95ºC for 20 sec, 60ºC for 20 sec, 72ºC for 34 sec. Quantities of the specific mRNA in the sample were measured according to the corresponding gene specific standard. The mRNA encoding G3PDH was used as internal invariant control to normalize the expression of the cytokine-expressing genes. Data were shown as copies of cytokine-specific mRNA/10 6 copies of G3PDH-specific mRNA (1) .
Comparison of immunogenicity of BCG and sigE mutant vaccinated mice before challenge. To study bacterial growth and ability to disseminate, we determined CFU in different organs after subcutaneous vaccination (1) .
Groups of four BALB/c mice were vaccinated by inoculating the best protective dose of live bacilli (8000 cells, determined as described above, data not shown)
subcutaneously at the base of the tail, After animal vaccination, aliquots of the bacterial inoculum were plated to confirm the number of cfu administrated to the animals.
Animals were killed at 15, 30 and 60 days post-vaccination. The inguinal lymph nodes, spleen, lungs, and the subcutaneous tissue at the site of vaccination (base of the tail) were immediately dissected and homogenized for determination of bacillary loads by CFU quantification following the same procedure described above.
Another group of four vaccinated BALB/c mice per time point was used to determine immunogenicity by comparing the production of IFN-γ by cell suspensions from inguinal lymph nodes, spleen and lungs after stimulation with mycobacterial culture filtrate antigens (CFA), or the immunodominant recombinant antigens ESAT-6, Hsp65
and Ag85 (1) . After killing the mice, spleen, inguinal lymph nodes and lungs were immediately removed, placed in 2 ml of RPMI medium containing 0.5 mg/ml collagenase type 2 (Worthington, NJ, USA), and incubated 1 hour at 37ºC. Samples were then passed through a 70-µm cell sieve, crushed with a syringe plunger, and rinsed with the medium. Cells were centrifuged at 1500 rpm for 5 min and the supernatant was removed; red cells were eliminated with a lysis buffer. After washing, cells were resuspended in RPMI medium supplemented with 2 mM L-glutamine, 100 U of penicillin per ml, 1µg of streptomycin per ml (Sigma), and 10% fetal calf serum.
Cultures for cytokine production (10 6 cells in 1 ml of culture medium) were performed in flat-bottomed 24-well plates without and with mycobacterial antigens (CFA, ESAT-6, Hsp65, and Ag85). 
RESULTS
Characterization of the sigE mutant pathogenicity after intra-tracheal administration. In order to characterize the sigE mutant attenuation in our model, groups of BALB/c mice (70 per group) were infected intratracheally with 2.5 x 10 5 CFU of H37Rv, the sigE mutant, or its complemented strain. All the animals infected with the sigE mutant survived after four months of infection. In contrast, mice inoculated with the complemented or parental strain started to die at three weeks post-infection and all had died by 8 weeks (Fig 1A) . These survival rates well correlated with the CFU in lung homogenates. During the first and second week of infection, similar numbers of CFU were detected in the three groups, whereas after day 21 and 28 post-infection significantly lower bacterial loads were found in mice infected with the sigE mutant, compared to those detected in animals infected with the parental or complemented strains (Fig 1B) . At day 60 and 120, animals infected with the mutant strain still showed a low bacterial burden, while the other animals were dead.
The histopathological analysis showed inflammatory infiltrate predominantly constituted by lymphocytes and activated macrophages (large cells with compact cytoplasm and nucleus with apparent nucleoli) in the alveolar-capillary interstitium and around small blood vessels and bronchial walls after one and two weeks of the infection with either of the strains, being higher in animals infected with the sigE mutant which showed well formed granulomas after 7 days of infection, while the mice infected with the parental or complemented strains showed granulomas after two weeks of infection.
After 28 days post-infection only H37Rv induced a significant pneumonia involving about 30% of the lung surface. By contrast, in mice infected with the sigE mutant, well formed granulomas and comparable pneumonia appeared only after 60 and 120 days post-infection, when the animals infected with H37Rv or the complemented strain were all dead (data not shown). and β-defensin 3 ( Fig. 2) , as well as a progressive induction of iNOS expression in late time points (Fig. 2 ). Also expression of IL-10 was higher in sigE infected mice, but only from 21 and 28 days after the infection (Fig. 2) . The only cytokine shown to be expressed at a significant lower level in the sigE infected animals was IL-4 ( Fig. 2) .
Evaluation of cytokine, iNOS and
Comparison of sigE mutant and BCG attenuation in mice. In order to compare the virulence of the sigE mutant to that of BCG, groups of BALB/c mice (12 per group)
were inoculated subcutaneously with 8000 CFU of either of these two bacterial strains.
Two weeks after inoculum, animals which received the sigE mutant showed a significant two-fold higher bacterial load at the inoculation site and in the lungs.
However, at days 30 and 60 post-vaccination, both groups of vaccinated animals showed similar bacillary loads in the inoculation site, inguinal lymph nodes, spleen and lungs (Fig 3) , suggesting that the sigE mutant is not more virulent than BCG in mice.
To further investigate the virulent potential of the sigE mutant strain compared to that of BCG, we compared the survival rate of nude mice (20 per group) inoculated subcutaneously with 8000 CFU of either of the two bacterial strains. Results, shown in Figure 4 show that, even if no significative difference in the 50% survival time point
was found between the two groups, at the end of the experiment there was a significant difference among the survival between the two groups suggesting that the sigE mutant is more attenuated than BCG in these immunodeficient animals. These observations justify the hypothesis that the sigE mutant could have a strong potential as a novel attenuated vaccine, since the response to its infection fits well into the proposition that the aim of a "classical" vaccine is to mimic natural infection as closely as possible inducing a strong immune protective response without causing extensive disease (39). In addition, the lack of a Th-2 response in the presence of a strong Th-1 response is considered one of the essential characteristics for a new antitubercular vaccine (34-36). Moreover, the sigE mutant can be considered a good vaccine candidate since it is highly attenuated in SCID mice (27), and at the latest time points produces a significant lower mortality than BCG in nude mice. This is of particular importance, since one of the problems of BCG is that it can cause disease in immuno-compromised patients, so a new attenuated vaccine strain should be more attenuated than BCG in this kind of patients. Finally, another promising observation was that after vaccination and before challenge, spleen and lung cell suspensions stimulated with mycobacterial antigens from mice vaccinated with the sigE mutant were more efficient in the production of IFN-γ than those from animals vaccinated with BCG.
Comparison of sigE
Taken together these observations suggest that the sigE mutant is safer and more immunogenic than BCG.
Beside the down-regulation of the genes in the σ E regulon, some of which are involved in surface biology, σ E absence has a pleiotropic effect on the bacterial surface, as demonstrated by the transcriptional profile of the sigE mutant after in-vitro macrophage infection, showing the induction of genes related to cell wall structure and protein secretion (13). Thus, the sigE mutant might have cell envelope defects resulting in both its attenuation and its high immunogenicity. We are currently comparing the composition of the cell envelope and secretome of the sigE mutant and wild type parental strain H37Rv in order to identify differences that could be the basis of their different pathogenic and immunogenic behaviour.
Several mycobacterial mutants have already been demonstrated to have good potential as new efficient vaccine (reviewed in 10), and three of them have been analyzed using the model of infection used in this paper: ì) a mutant lacking phoP, which was able to induce similar protection to that of BCG (1); ii) a mutant lacking fadD26 (which lacks the cell wall lipid complex phthiocerol dimycocerosate), which conferred 70% survival after four months of challenge with the highly virulent strain Beijing 9501000, but on September 20, 2017 by guest http://iai.asm.org/
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showed only a partial attenuation (21); iii) a mutant lacking the mammalian cell entry gene 2 (mce2), which was severely attenuated and induced a 72% survival after four months of challenge with the highly virulent strain Beijing 9501000 (2). We show here that the sigE mutant is as attenuated as the mce2 mutant, but induced better protection, allowing 80% mice survival after four months of challenge with strain Beijing 9501000.
Interestingly, mice infected with the mce2 mutant, in contrast to those infected with the sigE mutant, produced significatively less IFN-γ than those infected with the wild type strain and did not produce more TNF-α. Thus, the sigE mutant is until now the best vaccine candidate tested in this experimental mouse model.
In our experiments the level of BCG-induced protection was lower than that usually provided by this vaccine. This could be explained by the fact that the mice used in this study received Mexico City autoclaved, but not filtered, tap water, known to contain high loads of environmental mycobacteria. Pre-exposure to these environmental mycobacteria probably resulted in a basal level of immunization against mycobacterial antigens, which have been hypothesized to cause poor responsiveness to BCG vaccination (34, 36).
Further experiments in other animal models in which the protective potential of BCG is higher than that obtainable in our model, are needed to confirm the superiority of the protective potential of the sigE mutant with respect to BCG.
We conclude that these results encourage further studies of the sigE mutant as a potential vaccine strain; for this purpose, the construction of a double mutant in order to create a more attenuated and highly immunogenic mutant or the over expression of protective antigens in this strain could represent valuable strategies for further developments. 
